Le Lézard
Classified in: Health, Business
Subjects: TDS, TRI

PharmaMar: Sylentis Presents New Data on a New Eye Drop siRNA for the Treatment of Retinal Diseases Avoiding Intraocular Injections


MADRID, September 25, 2017 /PRNewswire/ --

Sylentis presents, for the first time, positive data on the efficacy of SYL136001v10, a siRNA (small interference RNA) for the treatment of neovascular diseases of the retina such as Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR). SYL136001v10 reaches the retina when administered topically, demonstrating that the siRNA may be applied in eye drops changing the treatment paradigm for patients suffering these diseases. "Currently, patients are treated in a hospital setting where they receive anti-VEGFs by intraocular injection. This procedure is not only painful and uncomfortable for the patient but also entails increasing financial commitments for our national health system," notes Covadonga Pañeda, R&D Manager at Sylentis, and principal author of the studies.


     (Logo: http://photos.prnewswire.com/prnh/20150203/727958-b )

The data will be presented at the XIII Annual Meeting of the Oligonucleotide Therapeutics Society (OTS) taking place in Bourdeaux, France between the 24th and the 27th of September and where the latest advances in oligonucleotide therapeutics will be presented.

Sylentis has identified NRARP (NOTCH-regulated Ankyrin Repeat Protein) as a potential target for the treatment of angiogenic diseases of the retina. NRARP is a key regulator of the molecular pathways leading to vessel formation; as such, the consequences of modulating the expression of this gene with RNAi has been studied in animal models of retinal neovascularization.

The results of the efficacy studies have shown that reduction of NRARP in the retina using RNAi leads to regression of neovascular lesions and that the lesion reductions observed are equivalent to those observed in response to anti-VEGF treatment, current standard treatment administered by intraocular injection.

Sylentis studies at the XIII Annual Meeting of the Oligonucleotide Therapeutics Society:  

Session: September 24th 18:30 to 20:30 horas. Presenting author: Covadonga Pañeda et al. R&D Manager, Sylentis, España.

Session: September 25th 17:00 to 19:30 horas. Presenting author: Covadonga Pañeda et al. R&D Manager, Sylentis, España.

Media Contacts:
Media Relations (+34-638-79-62-15)
Investor Relations (+34-914444500)


SOURCE PharmaMar


These press releases may also interest you

at 11:52
Ted B. Miller,...

at 11:50
PenFed Credit Union, America's second-largest federal credit union, today announced it joined with the Porsche Carrera Cup North America to become the presenting partner of the final two races in the 2024 championship. PenFed will join the...

at 11:48
Benjamin Capital Partners announced today the closing of a seed round, raising a total of $5.5 mil. from Play Ventures & F4 Fund. Other prominent investors in the round include inventor, investor, and serial...

at 11:45
Ternary, a leader in multi-cloud FinOps software for enterprises, announced the addition of Yalei Wang to its executive team as Vice President of Product Delivery. Wang steps into his new role with over two decades of software engineering and...

at 11:31
ICIS, a global source of commodity intelligence, is pleased to announce a strategic partnership with Base Oil News, a premier news outlet founded by industry expert Iain Pocock that provides in-depth coverage of the base oils and lubricants market....

at 11:30
SharpQuest, Inc., a software services provider with a niche in cloud and mobile-app solutions, is thrilled to announce the opening of its new branch office in Windsor, Ontario, Canada. This strategic expansion marks a significant milestone in our...



News published on and distributed by: